Harriet Kluger and co-workers from the Medical Oncology of Yale School of Medicine published in Clinical Cancer Research has found that expression of high levels of TRAIL-R2 causes a decrease in survival rates of breast cancer patients.
TRAIL receptors are cell surface receptors that triggers cell death, the study has found that TRAIL-R1 expression was not associated with survival, high TRAIL-R2 expression strongly correlated with decreased survival. The study was conducted using an Automated Quantitative Analaysis System (AQUATM), to study the tissue by microarray specimens.
"A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies," said Harriet Kluger, MD, author on the study and Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. By using AQUATM analysis on patients based on expression levels of drug targets in an automated, unbiased method and this will help to find out personalized treatment method for treating patients based on individual tumors.
"AQUATM allows us to stratify patients based on expression levels of drug targets in an automated, unbiased fashion. This will help us reach our ultimate goal of practicing personalized medicine, by treating patients based on characteristics of individual tumors,"
Further Information on Breast Cancer from Medindia:
Breast cancer is the most common type of cancer among women. Breast cancer mostly occurs in women over the age of 50, and the risk is especially high for women over age 60. Breast cancer is also found to occur more often in white women than African American or Asian women.
For More information on Breast Cancer: